ClinicalTrials.gg
RecruitingNCT04103372PRESERVEUpdated Nov 4, 2024

Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery

An interventional study of MRI scan and Radiologist training in Rectal Cancer and Colo-rectal Cancer, sponsored by Imperial College London. Recruiting at 23 sites in United Kingdom. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
16 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Rectal Neoplasms with a site in United Kingdom — 16 open to participants now, 26 under way, 5 of them phase 3. Rectal Neoplasms · United Kingdom.

Planned enrollment
30th of 78
200 · median 115
Started
2024
with 1 other
No phase
26 of 113
6 open now
Primary completion
2026-12
later than 12 of 25 live
Registered
84th of 113
by date
Lead sponsor
9 of 113
Imperial College London

Among the 113 studies in Rectal Neoplasms with a site in United Kingdom, this one is the 30th largest by planned enrollment of the 78 interventional ones that give a count, is one of 2 that started in 2024, is one of 26 with no phase, reaches primary completion later than 12 of the 25 other live ones, and was the 84th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

16 of the 113 studies in Rectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 16 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Rectal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

When a patient is diagnosed with a rectal (bowel) polyp or cancer, radiology doctors read MRI scans to describe how deeply the cancer invades into the bowel wall (this is the 'stage' of the cancer). In this project, we will teach radiologists to find more early-stage rectal cancers. These are cancers that have only grown partially into the bowel wall. If we succeed, more patients could have these lesions removed by a local procedure that preserves the bowel and avoids the risks and complications of major surgery.

We have developed a new method for radiology doctors to read MRI scans, which is more accurate than current practice. Currently only 3/10 of early rectal cancers are found by radiologists but by using our MRI reading system, 9/10 patients can be accurately identified as having early rectal cancer. We have proven that we can teach this method to other radiology doctors whose reports help to accurately inform patients of all possible treatment options, so they can be offered the option of a local procedure.

In this initial work we will train radiology doctors in our MRI reading method in 20 hospitals. We will compare MRI reports before and after training to see if an accurate reading method improves treatments choices for patients. We will also determine whether more patients have local procedures after our training. The results of this initial work will help us to apply for national funding for a trial that we can quickly roll out to all NHS hospitals.

Read the detailed description

Many patients diagnosed with Early Rectal Cancer (ERC) are currently over-treated. Most patients with confirmed ERC will undergo an MRI, but some are not correctly identified in endoscopy and immediately removed. Of those who undergo MRI, 69% are over-staged and undergo major surgery or unnecessary radiotherapy when local excision surgery to preserve the patients rectum, and quality of life, would have been possible. \<10% of patients with ERC are staged accurately and offered local excision, with the majority who are staged as ERC on MRI still undergoing major surgery, likely due to uncertainty in the staging report.

Prof Gina Brown developed a more accurate radiological staging system (PRESERVE) or ERC, whereby T2 tumours are identified and classified according to the degree of preservation of the individual layers of the rectal wall. It has been shown that PRESERVE enabled better identification of ERC suitable for local excision from the expected 30% to 89% accuracy. This improved accuracy was replicated in a further study by training a cohort of 12 radiologists. It is predicted that wider adoption of PRESERVE will result in increased organ-preserving surgery from the current rates of 10% to >50%.

03

Conditions studied

  • Rectal Cancer
  • Colo-rectal Cancer

Keywords

  • early stage
  • early phase
  • Endoscopic Mucosal Resection
  • Endoscopic Submucosal Dissection
  • Histopathological Staging
  • MDT Decision Making
  • MRI Staging
  • Quality of Life
  • Radiotherapy
  • Rectal preservation
  • Shared decision making
  • Significant Rectal Polyps
  • Transanal Endoscopic Microsurgery
  • Transanal Minimally Invasive Surgery
04

Who can participate

Ages eligible
16 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a rectal tumour or suspected tumour less than or equal to T3b on MRI stage or pT2 or less after excision, or 20mm or more on endoscopy with suspicion of
  2. Be aged 16 years or over

Exclusion criteria

Exclusion Criteria:

  1. Have disease at time of initial staging
  2. Have a -proven rectal which is not adenocarcinoma
  3. Are for MRI
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Control Arm Schedule

    All sites will begin in the Control arm, with patients recruited to the Control Arm Schedule. Clinical investigations prior to treatment, during treatment, after surgery and during further treatment should be performed as per standard clinical practice and as clinically indicated. Each site will transition to the Intervention arm at a month prescribed by their randomised cluster, and from that point patients are recruited to the Intervention Arm Schedule . Patients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point.

  • Experimental
    Intervention Arm Schedule

    Each site will transition to the Intervention arm at a month prescribed by their randomised cluster, and from that point patients are recruited to the Intervention Arm Schedule . The transition period lasts one month during which recruitment is halted and two interventions implemented: 1. MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy. 2. Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer. Patients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point.

    Diagnostic Test: MRI scan · Other: Radiologist training

Interventions

  • Diagnostic testMRI scan

    MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.

  • OtherRadiologist training

    Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.

06

What researchers measure

Primary outcomes

  1. Impact of a training intervention on the accuracy of the tumour staging diagnosis through systematic reporting approach to MRI scans against current (pre intervention) practice.

    Comparison of the proportion of patients with early rectal cancer who are diagnosed by pathology vs those staged as such by MRI, before and after the intervention.

    Time frame: 1 year

Secondary outcomes

  1. Proportion of patients with technically adequacate scans before and after intervention

    Proportion of patients scanned with high resolution MR in the correct planes

    Time frame: 1 year

  2. Proportion of primary tumour characterised by morphology and other features associated with malignancy before and after intervention

    Proportion of reports where primary tumour has been characterised by morphology before and after intervention in i) endoscopy, ii) radiology reports before and after intervention

    Time frame: 1 year

  3. Proportion of MRI reports with T substage given before and after intervention

    Proportion of reports where T substage of primary tumour has been recorded before and after intervention

    Time frame: 1 year

  4. Number of patients identified on imaging as suitable for rectal preservation by local excision

    Proportion of imaging reports where suitable patients are identified on the report as suitable for rectal preservation by local excision being identified by the radiologist on the report before and after intervention

    Time frame: 1 year

  5. Number of patients identified by MDT as suitable for rectal preservation by local excision

    Proportion of MDT decisions where patients suitable for rectal preservation by local excision are identified and comparison of treatments offered to patients by the MDT, before and after the intervention

    Time frame: 1 year

  6. Correlation of accuracy in the identification of safe plane of excision for rectal preservation by the radiologist

    Proportion of patients with \>1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients with \>1mm submucosa preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients undergoing TME that have \<1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention

    Time frame: 1 year

  7. Numebr of patients with R0 by local excision or TME as appropriate

    Proportion of patients with R0 that have \>1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients with R0 that have\>1mm submucosa preserved on histopathology identified as such by the radiologist before and after intervention Proportion of patients undergoing TME with R0 that have \<1mm muscularis preserved on histopathology identified as such by the radiologist before and after intervention

    Time frame: 1 year

  8. Qualitative EORTC QLQ-CR29 Questionnaire on Quality of Life of patients undergoing local excision vs major surgery

    Comparison of QoL EORTC QLQ-CR29 scores before and after intervention. Questions relate to difficulty in performing every day tasks answers are rated 'Not at all' 'A Little' 'Quite a Bit' 'Very Much'

    Time frame: 1 year, 3 years, 5 years

  9. Qualitative EORTC QLQ-CR30 Questionnaire on Quality of Life of patients undergoing local excision vs major surgery

    Comparison of QoL EORTC QLQ-CR30 scores before and after intervention. Questions relate to the presences of symptoms over the previous week answers are rated 'Not at all' 'A Little' 'Quite a Bit' 'Very Much'

    Time frame: 1 year, 3 years, 5 years

  10. Qualitative LARS Questionnaire on Quality of Life of patients undergoing local excision vs major surgery

    Comparison of LARS scores before and after intervention. Questions relate to bowel function answers are rated 'Not at all' 'A Little' 'Quite a Bit' 'Very Much'

    Time frame: 1 year, 3 years, 5 years

  11. Qualitative Questionnaire on Quality of Life of patients undergoing local excision vs major surgery

    Comparison of self evaluation of overall health and quality of life scores before and after intervention. Answers are rated from 1 very poor to 7 excellent

    Time frame: 1 year, 3 years, 5 years

  12. Comparison of total costs of procedures performed between patients undergoing local excision surgery to those undergoing major surgery

    Comparison of total costs of hospital procedures performed based on individual pathways before and after intervention

    Time frame: 1 year

  13. Comparison of inpatient costs between patients undergoing local excision surgery to those undergoing major surgery

    Comparison of cost of inpatient episodes based on individual pathways before and after intervention

    Time frame: 1 year

  14. Comparison of total cost of outpatient visits between patients undergoing local excision surgery to those undergoing major surgery

    Comparison of total cost of outpatient episodes based on individual pathways before and after intervention

    Time frame: 1 year

  15. Comparison of total community costs between patients undergoing local excision surgery to those undergoing major surgery

    Comparison of total cost of treatments delivered in the community based on individual pathways before and after intervention

    Time frame: 1 year

  16. Number of patients without disease and/or without stoma between patients undergoing local excision surgery, compared to those undergoing major surgery

    DFS and stoma free survival in patients based on individual pathways before and after intervention

    Time frame: 1 year, 3 years, 5 years

  17. Assessment results for the effectiveness of mrSRT after a year from training

    Determine longevity of training by assessment of radiologists trained with the PRESERVE mrSRT accuracy 1 year after training

    Time frame: 1 year

  18. Identification of histopathological biomarkers to improve selection of patients who can undergo rectal preserving strategies for Early Recal Cancer

    Comparison of relative % histopathological biomarkers screening panels between patients identified on imaging as suitable for rectal preservation by local excision being identified by the radiologist on the report before and after intervention

    Time frame: 2 months, 1 year, 3 years, 5 years

07

Study locations

1 of 23 sites recruiting
08

References and documents

Publications

  • Detering R, van Oostendorp SE, Meyer VM, van Dieren S, Bos ACRK, Dekker JWT, Reerink O, van Waesberghe JHTM, Marijnen CAM, Moons LMG, Beets-Tan RGH, Hompes R, van Westreenen HL, Tanis PJ, Tuynman JB; Dutch ColoRectal Audit Group*. MRI cT1-2 rectal cancer staging accuracy: a population-based study. Br J Surg. 2020 Sep;107(10):1372-1382. doi: 10.1002/bjs.11590. Epub 2020 Apr 16. PubMed 32297326 ↗
  • Balyasnikova S, Read J, Wotherspoon A, Rasheed S, Tekkis P, Tait D, Cunningham D, Brown G. Diagnostic accuracy of high-resolution MRI as a method to predict potentially safe endoscopic and surgical planes in patients with early rectal cancer. BMJ Open Gastroenterol. 2017 Aug 14;4(1):e000151. doi: 10.1136/bmjgast-2017-000151. eCollection 2017. PubMed 29259791 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 27 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2019
First posted
Sep 25, 2019
StartActual
Sep 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2031
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04103372
Collaborators
Pelican Cancer Foundation, RM Partners West London Cancer Alliance
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Sep 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 4, 2024

Study contacts

Caroline Martin
Contact
c.martin1@imperial.ac.uk
+44 (0) 7749 655 817
Syvella Ellis
Contact
giclinicaltrials@imperial.ac.uk
+44 (0) 7732 315 234
Gina Brown, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion